Literature DB >> 2839099

Serial determination of platinum, protein content and free sulfhydryl levels in plasma of patients treated with cisplatin or carboplatin.

F Tosetti1, M Rocco, R A Fulco, S Chiara, M Bruzzone, E Campora, M Esposito.   

Abstract

We report here the results of serial determinations of free-sulfhydryl, protein content and platinum levels in plasma of cancer patients following either cisplatin (cis-DDP, 3 patients, 60 mg/m2) or carboplatin (JM-8, 3 patients, 300 mg/m2) i.v. administration. After treatment with cis-DDP, significant platinum binding to plasma components with MW greater than 25 kD was observed; the ratio free-sulfhydryls/protein content decreased during the first two hours, returning to normal values at 24 hours after injection. In contrast, no evidence of platinum binding to plasma components with MW greater than 25 kD was noted after JM-8 i.v. administration, and the ratio free sulfhydryls/protein content did not change significantly after treatment. In vitro experiments show that at a molar ratio cis-DDP:JM-8 1:10, the two compounds bind to low MW thiols with the same kinetics. These data seems to suggest different interactions at the plasma level of these drugs, which may be correlated with their different toxicity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839099

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Effects of storage on the binding of carboplatin to plasma proteins.

Authors:  K Erkmen; M J Egorin; L M Reyno; R Morgan; J H Doroshow
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 2.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

3.  Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin.

Authors:  R Leone; M E Fracasso; E Soresi; G Cimino; M Tedeschi; D Castoldi; V Monzani; L Colombi; T Usari; A Bernareggi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.